
AroCell Q1 - Unrecognized and going well

Redeye makes some minor estimate changes following the report (lowering sales from TUBEX in Africa), but we are encouraged to hear more concrete information about its Chinese partner, ZECEN. Sales came in line, and the gross margin and OPEX were better than expected.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[AroCell Q1 - Unrecognized and going well](#)